Literature DB >> 19530415

Epidemiologic, clinical and socioeconomic factors of atopic dermatitis in Spain: Alergológica-2005.

A Martorell Aragonés1, R Félix Toledo, A Martorell Calatayud, J C Cerdá Mir.   

Abstract

OBJECTIVE: To analyze the clinical and epidemiologic characteristics of the population with atopic dermatitis (AD) consulting in Allergology services in Spain.
MATERIALS AND METHODS: The study was a multi-center, observational, descriptive, cross-sectional epidemiologic study with prospective collection of data on patients consulting for the first time in Allergology services in Spain. By means of a data collection record, personal and specific variables were collected during the calendar year 2005 from a total of 4991 patients with AD.
RESULTS: AD was diagnosed in 171 patients (3.4% of patients seen in Allergology services), which represented no significant change with regard to the Alergológica-1992 study. In 72% of cases, AD was associated with other allergic disorders. The mean age of the onset of clinical manifestations of AD was 1 year and 4 months. During the first consultations, the suspected diagnosis of AD was established in 83% of cases. In 58% of cases the cause was considered idiopathic and 42% were associated with sensitization to allergens. In 10% of patients with AD the triggering allergens were foods and in 26% aeroallergens. Most patients (94%) received hydrating skin and drug treatment (anti-histamines 73%, topical corticoids 49%, calcineurin inhibitors 31%). Only 10% of patients followed an exclusion diet.
CONCLUSIONS: No significant increase in the demand for AD consultations was observed in comparison with Alergológica-1992. AD was frequently associated with other allergic disorders. In few cases was food involved in the etiology of the disease. In most cases nothing more than topical drug treatment was indicated.

Entities:  

Mesh:

Year:  2009        PMID: 19530415

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  5 in total

Review 1.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

2.  Atopic dermatitis is a serious health problem in Poland. Epidemiology studies based on the ECAP study.

Authors:  Adam J Sybilski; Filip Raciborski; Agnieszka Lipiec; Aneta Tomaszewska; Adam Lusawa; Piotr Samel-Kowalik; Artur Walkiewicz; Edyta Krzych; Jarosław Komorowski; Bolesław Samoliński
Journal:  Postepy Dermatol Alergol       Date:  2015-02-02       Impact factor: 1.837

Review 3.  A Systematic Scoping Literature Review of Publications Supporting Treatment Guidelines for Pediatric Atopic Dermatitis in Contrast to Clinical Practice Patterns.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Paola Mina-Osorio
Journal:  Dermatol Ther (Heidelb)       Date:  2018-06-01

4.  Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey.

Authors:  Joaquín Sastre; Esther Serra Baldrich; José Carlos Armario Hita; L Herráez; Ignacio Jáuregui; Ana Martín-Santiago; Javier Ortiz de Frutos; Juan Francisco Silvestre; Antonio Valero
Journal:  Dermatol Res Pract       Date:  2020-04-07

5.  Epidemiology and direct costs of atopic dermatitis in Poland based on the National Health Fund register (2008-2017).

Authors:  Filip Raciborski; Karina Jahnz-Rozyk; Anna Kłak; Adam J Sybilski; Aleksandra M Grąbczewska; Melania Brzozowska; Andrzej M Śliwczyñski
Journal:  Postepy Dermatol Alergol       Date:  2018-10-19       Impact factor: 1.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.